PPOS ve EPOS Uygulaması ve Etki Mekanizması
Özet
Referanslar
Zhu S, Lv Z, Song L, Zhang Q, Fan Y, Li J. Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment. Open Med (Wars). 2022 Nov 21;17(1):1811-1820. doi: 10.1515/med-2022-0594. PMID: 36457798; PMCID: PMC9679556.
Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022.
Ata B, Capuzzo M, Turkgeldi E, Yildiz S, La Marca A. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. Hum Reprod Update. 2021 Jan 4;27(1):48-66. doi: 10.1093/humupd/dmaa040.
Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012 Jan-Feb;18(1):73-91. doi: 10.1093/humupd/dmr039. Epub 2011 Nov 8. PMID: 22068695.
Oktem O, Esmaeilian Y, İltumur E, Yusufoglu S, Çimen DU, Incir S, Yakin K, Ata B, Urman B. Exposure of antral follicles to medroxyprogesterone acetate during stimulation does not cause molecular perturbations in gonadotropin-responsiveness and steroidogenic function of granulosa cells in progestin-primed cycles. Hum Reprod. 2024 Oct 1;39(10):2331-2340. doi: 10.1093/humrep/deae189. PMID: 39180767.
Hamdi K, Farzadi L, Ghasemzadeh A, Navali N, Atashkhoei S, Pia H, Shahnazi V, Fattahi A, Bahrami-Asl Z, Sepasi F et al. Comparison of medroxyprogesterone acetate with cetrotide for prevention of premature luteinizing hormone surges in women undergoing in vitro fertilization. International journal of women's health and reproduction sciences 2018;6: 187‐191.
Welp AM, Williams CD, Smith LP, Purcell S, Goodman LR. Oral medroxyprogesterone acetate for the use of ovulation suppression in in vitro fertilization: a cohort trial. Fertil Steril. 2024 May;121(5):806-813. doi: 10.1016/j.fertnstert.2024.01.026. Epub 2024 Jan 20.
Guan S, Feng Y, Huang Y, Huang J. Progestin-Primed Ovarian Stimulation Protocol for Patients in Assisted Reproductive Technology: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne). 2021 Aug 31;12:702558. doi: 10.3389/fendo.2021.702558. PMID: 34531825; PMCID: PMC8438422.
Deng R, Wang J, He J, Lei X, Zi D, Nong W, Lei X. GnRH antagonist protocol versus progestin-primed ovarian stimulation in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024 Apr;309(4):1151-1163. doi: 10.1007/s00404-023-07269-1. Epub 2023 Nov 13.
Ozgur K, Berkkanoglu M, Bulut H, Donmez L, Coetzee K. Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all IVF cycles. J Assist Reprod Genet. 2020 Sep;37(9):2337-2345. doi: 10.1007/s10815-020-01894-4.
Chen H, Teng XM, Sun ZL, Yao D, Wang Z, Chen ZQ. Comparison of the cumulative live birth rates after 1 in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: a propensity score-matched study. Fertil Steril. 2022 Oct;118(4):701-712. doi: 10.1016/j.fertnstert.2022.06.012.
Cai H, Shi Z, Liu D, Bai H, Zhou H, Xue X, Li W, Li M, Zhao X, Ma C, Wang H, Wang T, Li N, Wen W, Wang M, Zhang D, Mol BW, Shi J, Tian L. Flexible progestin-primed ovarian stimulation versus a GnRH antagonist protocol in predicted suboptimal responders undergoing freeze-all cycles: a randomized non-inferiority trial. Hum Reprod. 2025 Feb 1;40(2):319-327. doi: 10.1093/humrep/deae286. PMID: 39729571.
Turkgeldi E, Yildiz S, Cekic SG, Shakerian B, Keles I, Ata B. Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve. Hum Fertil (Camb). 2022 Apr;25(2):306-312. doi: 10.1080/14647273.2020.1794060. Epub 2020 Jul 16. PMID: 32672129.
Lin G, Zhong X, Li S, Liu X, Xu L. The clinical value of progestin-primed ovarian stimulation protocol for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 Aug 21;14:1232935. doi: 10.3389/fendo.2023.1232935. PMID: 37670890; PMCID: PMC10476097.
Xu S, Wang X, Zhang Y, Han Y, Zhang C. Comparison the effects of progestin-primed ovarian stimulation (PPOS) protocol and GnRH-a long protocol in patients with normal ovarian reserve function. Gynecol Endocrinol. 2023 Dec;39(1):2217263. doi: 10.1080/09513590.2023.2217263. PMID: 37236243.
Sun Q, Cao Y, Gu J, Xu Y. The application of progesterone-primed ovarian stimulation protocol in patients with ovarian endometriosis combined with diminished ovarian reserve. BMC Womens Health. 2025 Feb 18;25(1):70. doi: 10.1186/s12905-025-03601-w.
Yang AM, Feng TF, Han Y, Zhao ZM, Wang W, Wang YZ, Zuo XQ, Xu X, Shi BJ, Li L, Hao GM, Cui N. Progestin-Primed Ovarian Stimulation Protocol for Patients With Endometrioma. Front Endocrinol (Lausanne). 2022 Apr 28;13:798434. doi: 10.3389/fendo.2022.798434. PMID: 35574014; PMCID: PMC9096226.
Vidal MDM, Martínez F, Rodríguez I, Polyzos NP. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles. Hum Reprod. 2024 May 2;39(5):1098-1104. doi: 10.1093/humrep/deae047. PMID: 38498835.
Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Quan X, Lyu Q, Kuang Y, Ai A. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human reproduction (Oxford, England) 2018;33: 229-237.
Zhang J, Du M, Li Z, Liu W, Ren B, Zhang Y, Guan Y. Comparison of Dydrogesterone and Medroxyprogesterone in the Progestin-Primed Ovarian Stimulation Protocol for Patients With Poor Ovarian Response. Front Endocrinol (Lausanne). 2021 Sep 24;12:708704. doi: 10.3389/fendo.2021.708704. PMID: 34630325; PMCID: PMC8498200
Huang J, Xie Q, Lin J, Lu X, Zhu J, Gao H, Cai R, Kuang Y. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study. Drug Des Devel Ther. 2019 Dec 31;13:4461-4470. doi: 10.2147/DDDT.S230129.
Kalafat E, Dizdar M, Turkgeldi E, Yildiz S, Keles I, Ata B. The Comparison of Fixed and Flexible Progestin Primed Ovarian Stimulation on Mature Oocyte Yield in Women at Risk of Premature Ovarian Insufficiency. Front Endocrinol (Lausanne). 2022 Feb 3;12:797227. doi: 10.3389/fendo.2021.797227. PMID: 35185784; PMCID: PMC8850276.
Matsuda Y, Takebayashi A, Tsuji S, Hanada T, Kasei R, Hirata K, Murakami T. Comparison of fixed and flexible progestin-primed ovarian stimulation in women classified in patient-oriented strategies encompassing individualized oocyte number (POSEIDON) group 4. Arch Gynecol Obstet. 2024 Oct;310(4):2203-2209. doi: 10.1007/s00404-024-07690-0.
Chen Y, Chu Y, Yao W, Wang L, Zeng W, Yue J. Comparison of Cumulative Live Birth Rates between Flexible and Conventional Progestin-Primed Ovarian Stimulation Protocol in Poor Ovarian Response Patients According to POSEIDON Criteria: A Cohort Study. J Clin Med. 2023 Sep 5;12(18):5775. doi: 10.3390/jcm12185775. PMID: 37762716;
Doğan Durdağ G, Bektaş G, Türkyılmaz E, Göktepe H, Sönmezer M, Şükür YE, Özmen B, Atabekoğlu C, Berker B, Aytaç R, Sönmezer M. The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. J Turk Ger Gynecol Assoc. 2021 Dec 6;22(4):293-299. doi: 10.4274/jtgga.galenos.2020.2020.0110. Epub 2021 Jan 4.
Qin X, Fan L, Luo Y, Deng Z, Zeng Z, Jiang X, Yang Y. Progestin-primed ovarian stimulation (PPOS) in preimplantation genetic testing for aneuploidy: a retrospective study and meta-analysis. Arch Gynecol Obstet. 2025 Feb 13. doi: 10.1007/s00404-024-07918-z.
Wang L, Wang J, Zhang Y, Qian C, Wang X, Bai J, Li F, Chen Z, Ai A. Analysis of euploidy rates in preimplantation genetic testing for aneuploidy cycles with progestin-primed versus GnRH agonist/antagonist protocol. Eur J Med Res. 2023 Jan 16;28(1):28. doi: 10.1186/s40001-023-01000-1. PMID: 36642707; PMCID: PMC9841681.
Lin Y, Chen Q, Zhu J, Teng Y, Huang X, Chen X. Progestin-Primed Ovarian Stimulation with Clomiphene Citrate Supplementation May Be More Feasible for Young Women with Diminished Ovarian Reserve Compared with Standard Progestin-Primed Ovarian Stimulation: A Retrospective Study. Drug Des Devel Ther. 2021 Dec 21;15:5087-5097. doi: 10.2147/DDDT.S338748. PMID: 34992345; PMCID: PMC8710074.
Jiang X, Jiang S, Diao H, Deng K, Zhang C. Progestin-primed ovarian stimulation protocol with or without letrozole for patients with normal ovarian reserve: a retrospective cohort study. J Clin Pharm Ther. 2022 Apr;47(4):469-476. doi: 10.1111/jcpt.13567.
Ovarian Stimulation for IVF/ICSI Guideline of the European Society of Human Reproduction and Embryology October 2019
Vaiarelli A, Pittana E, Cimadomo D, Ruffa A, Colamaria S, Argento C, Giuliani M, Petrone P, Fabozzi G, Innocenti F, Taggi M, Ata B, Rienzi L, Ubaldi FM. A multicycle approach through DuoStim with a progestin-primed ovarian stimulation (PPOS) protocol: a valuable option in poor prognosis patients undergoing PGT-A. J Assist Reprod Genet. 2025 Jan;42(1):255-264. doi: 10.1007/s10815-024-03317-0. Epub 2024 Nov 13.
Kalafat E, Turkgeldi E, Yıldız S, Dizdar M, Keles I, Ata B. Outcomes of a GnRH Agonist Trigger Following a GnRH Antagonist or Flexible Progestin-Primed Ovarian Stimulation Cycle. Front Endocrinol (Lausanne). 2022 May 19;13:837880. doi: 10.3389/fendo.2022.837880. PMID: 35663329; PMCID: PMC9161281.
Li Q, Li X, Li T, Xu L, Wang Y, Huang R. Comparison of an HCG-only trigger versus dual trigger for final oocyte maturation in a progestin-primed ovarian stimulation protocol. Reprod Biomed Online. 2022 Dec;45(6):1176-1181. doi: 10.1016/j.rbmo.2022.08.101.
Liang Z, Wang Y, Kuang Y. Live-Birth Outcomes and Congenital Malformations After Progestin-Primed Ovarian Stimulation in Maternal Endometriosis. Drug Des Devel Ther. 2020 Dec 10;14:5459-5467. doi: 10.2147/DDDT.S263138.
Huang J, Xie Q, Lin J, Lu X, Wang N, Gao H, Cai R, Kuang Y. Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019 Jul 26;13:2553-2563. doi: 10.2147/DDDT.S210228.
Zolfaroli I, Ferriol GA, Mora JH, Cano A. Impact of progestin ovarian stimulation on newborn outcomes: a meta-analysis. J Assist Reprod Genet. 2020 May;37(5):1203-1212. doi: 10.1007/s10815-020-01755-0. Epub 2020 Mar 25. PMID: 32215824; PMCID: PMC7244671.
Farquhar C, Rombauts L, Kremer JA, Lethaby A, Ayeleke RO. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. The Cochrane database of systematic reviews 2017;5: Cd006109.
Cédrin-Durnerin I, Carton I, Massin N, Chevalier N, Dubourdieu S, Bstandig B, Michelson X, Goro S, Jung C, Guivarc'h-Lévêque A. Pretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial. Hum Reprod. 2024 Sep 1;39(9):1979-1986. doi: 10.1093/humrep/deae167. PMID: 39008826.
Gleicher N, Mochizuki L, Barad DH. Time associations between U.S. birth rates and add-Ons to IVF practice between 2005-2016. Reprod Biol Endocrinol. 2021 Jul 13;19(1):110. doi: 10.1186/s12958-021-00793-2. PMID: 34256798; PMCID: PMC8278617.
Işıkoğlu M, de Mouzon J. The experience of in vitro fertilization data collection in Turkey. J Turk Ger Gynecol Assoc. 2021 Aug 31;22(3):235-241. doi: 10.4274/jtgga.galenos.2021.2020.0222. Epub 2021 May 3.
European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE); Smeenk J, Wyns C, De Geyter C, Kupka M, Bergh C, Cuevas Saiz I, De Neubourg D, Rezabek K, Tandler-Schneider A, Rugescu I, Goossens V. ART in Europe, 2019: results generated from European registries by ESHRE†. Hum Reprod. 2023 Dec 4;38(12):2321-2338. doi: 10.1093/humrep/dead197.
Glujovsky D, Pesce R, Miguens M, Sueldo C, Ciapponi A. Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle. Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD013827. doi: 10.1002/14651858.CD013827.pub2.
Referanslar
Zhu S, Lv Z, Song L, Zhang Q, Fan Y, Li J. Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment. Open Med (Wars). 2022 Nov 21;17(1):1811-1820. doi: 10.1515/med-2022-0594. PMID: 36457798; PMCID: PMC9679556.
Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022.
Ata B, Capuzzo M, Turkgeldi E, Yildiz S, La Marca A. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. Hum Reprod Update. 2021 Jan 4;27(1):48-66. doi: 10.1093/humupd/dmaa040.
Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012 Jan-Feb;18(1):73-91. doi: 10.1093/humupd/dmr039. Epub 2011 Nov 8. PMID: 22068695.
Oktem O, Esmaeilian Y, İltumur E, Yusufoglu S, Çimen DU, Incir S, Yakin K, Ata B, Urman B. Exposure of antral follicles to medroxyprogesterone acetate during stimulation does not cause molecular perturbations in gonadotropin-responsiveness and steroidogenic function of granulosa cells in progestin-primed cycles. Hum Reprod. 2024 Oct 1;39(10):2331-2340. doi: 10.1093/humrep/deae189. PMID: 39180767.
Hamdi K, Farzadi L, Ghasemzadeh A, Navali N, Atashkhoei S, Pia H, Shahnazi V, Fattahi A, Bahrami-Asl Z, Sepasi F et al. Comparison of medroxyprogesterone acetate with cetrotide for prevention of premature luteinizing hormone surges in women undergoing in vitro fertilization. International journal of women's health and reproduction sciences 2018;6: 187‐191.
Welp AM, Williams CD, Smith LP, Purcell S, Goodman LR. Oral medroxyprogesterone acetate for the use of ovulation suppression in in vitro fertilization: a cohort trial. Fertil Steril. 2024 May;121(5):806-813. doi: 10.1016/j.fertnstert.2024.01.026. Epub 2024 Jan 20.
Guan S, Feng Y, Huang Y, Huang J. Progestin-Primed Ovarian Stimulation Protocol for Patients in Assisted Reproductive Technology: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne). 2021 Aug 31;12:702558. doi: 10.3389/fendo.2021.702558. PMID: 34531825; PMCID: PMC8438422.
Deng R, Wang J, He J, Lei X, Zi D, Nong W, Lei X. GnRH antagonist protocol versus progestin-primed ovarian stimulation in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024 Apr;309(4):1151-1163. doi: 10.1007/s00404-023-07269-1. Epub 2023 Nov 13.
Ozgur K, Berkkanoglu M, Bulut H, Donmez L, Coetzee K. Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all IVF cycles. J Assist Reprod Genet. 2020 Sep;37(9):2337-2345. doi: 10.1007/s10815-020-01894-4.
Chen H, Teng XM, Sun ZL, Yao D, Wang Z, Chen ZQ. Comparison of the cumulative live birth rates after 1 in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: a propensity score-matched study. Fertil Steril. 2022 Oct;118(4):701-712. doi: 10.1016/j.fertnstert.2022.06.012.
Cai H, Shi Z, Liu D, Bai H, Zhou H, Xue X, Li W, Li M, Zhao X, Ma C, Wang H, Wang T, Li N, Wen W, Wang M, Zhang D, Mol BW, Shi J, Tian L. Flexible progestin-primed ovarian stimulation versus a GnRH antagonist protocol in predicted suboptimal responders undergoing freeze-all cycles: a randomized non-inferiority trial. Hum Reprod. 2025 Feb 1;40(2):319-327. doi: 10.1093/humrep/deae286. PMID: 39729571.
Turkgeldi E, Yildiz S, Cekic SG, Shakerian B, Keles I, Ata B. Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve. Hum Fertil (Camb). 2022 Apr;25(2):306-312. doi: 10.1080/14647273.2020.1794060. Epub 2020 Jul 16. PMID: 32672129.
Lin G, Zhong X, Li S, Liu X, Xu L. The clinical value of progestin-primed ovarian stimulation protocol for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 Aug 21;14:1232935. doi: 10.3389/fendo.2023.1232935. PMID: 37670890; PMCID: PMC10476097.
Xu S, Wang X, Zhang Y, Han Y, Zhang C. Comparison the effects of progestin-primed ovarian stimulation (PPOS) protocol and GnRH-a long protocol in patients with normal ovarian reserve function. Gynecol Endocrinol. 2023 Dec;39(1):2217263. doi: 10.1080/09513590.2023.2217263. PMID: 37236243.
Sun Q, Cao Y, Gu J, Xu Y. The application of progesterone-primed ovarian stimulation protocol in patients with ovarian endometriosis combined with diminished ovarian reserve. BMC Womens Health. 2025 Feb 18;25(1):70. doi: 10.1186/s12905-025-03601-w.
Yang AM, Feng TF, Han Y, Zhao ZM, Wang W, Wang YZ, Zuo XQ, Xu X, Shi BJ, Li L, Hao GM, Cui N. Progestin-Primed Ovarian Stimulation Protocol for Patients With Endometrioma. Front Endocrinol (Lausanne). 2022 Apr 28;13:798434. doi: 10.3389/fendo.2022.798434. PMID: 35574014; PMCID: PMC9096226.
Vidal MDM, Martínez F, Rodríguez I, Polyzos NP. Ovarian response and embryo ploidy following oral micronized progesterone-primed ovarian stimulation versus GnRH antagonist protocol. A prospective study with repeated ovarian stimulation cycles. Hum Reprod. 2024 May 2;39(5):1098-1104. doi: 10.1093/humrep/deae047. PMID: 38498835.
Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Quan X, Lyu Q, Kuang Y, Ai A. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human reproduction (Oxford, England) 2018;33: 229-237.
Zhang J, Du M, Li Z, Liu W, Ren B, Zhang Y, Guan Y. Comparison of Dydrogesterone and Medroxyprogesterone in the Progestin-Primed Ovarian Stimulation Protocol for Patients With Poor Ovarian Response. Front Endocrinol (Lausanne). 2021 Sep 24;12:708704. doi: 10.3389/fendo.2021.708704. PMID: 34630325; PMCID: PMC8498200
Huang J, Xie Q, Lin J, Lu X, Zhu J, Gao H, Cai R, Kuang Y. Progestin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study. Drug Des Devel Ther. 2019 Dec 31;13:4461-4470. doi: 10.2147/DDDT.S230129.
Kalafat E, Dizdar M, Turkgeldi E, Yildiz S, Keles I, Ata B. The Comparison of Fixed and Flexible Progestin Primed Ovarian Stimulation on Mature Oocyte Yield in Women at Risk of Premature Ovarian Insufficiency. Front Endocrinol (Lausanne). 2022 Feb 3;12:797227. doi: 10.3389/fendo.2021.797227. PMID: 35185784; PMCID: PMC8850276.
Matsuda Y, Takebayashi A, Tsuji S, Hanada T, Kasei R, Hirata K, Murakami T. Comparison of fixed and flexible progestin-primed ovarian stimulation in women classified in patient-oriented strategies encompassing individualized oocyte number (POSEIDON) group 4. Arch Gynecol Obstet. 2024 Oct;310(4):2203-2209. doi: 10.1007/s00404-024-07690-0.
Chen Y, Chu Y, Yao W, Wang L, Zeng W, Yue J. Comparison of Cumulative Live Birth Rates between Flexible and Conventional Progestin-Primed Ovarian Stimulation Protocol in Poor Ovarian Response Patients According to POSEIDON Criteria: A Cohort Study. J Clin Med. 2023 Sep 5;12(18):5775. doi: 10.3390/jcm12185775. PMID: 37762716;
Doğan Durdağ G, Bektaş G, Türkyılmaz E, Göktepe H, Sönmezer M, Şükür YE, Özmen B, Atabekoğlu C, Berker B, Aytaç R, Sönmezer M. The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation. J Turk Ger Gynecol Assoc. 2021 Dec 6;22(4):293-299. doi: 10.4274/jtgga.galenos.2020.2020.0110. Epub 2021 Jan 4.
Qin X, Fan L, Luo Y, Deng Z, Zeng Z, Jiang X, Yang Y. Progestin-primed ovarian stimulation (PPOS) in preimplantation genetic testing for aneuploidy: a retrospective study and meta-analysis. Arch Gynecol Obstet. 2025 Feb 13. doi: 10.1007/s00404-024-07918-z.
Wang L, Wang J, Zhang Y, Qian C, Wang X, Bai J, Li F, Chen Z, Ai A. Analysis of euploidy rates in preimplantation genetic testing for aneuploidy cycles with progestin-primed versus GnRH agonist/antagonist protocol. Eur J Med Res. 2023 Jan 16;28(1):28. doi: 10.1186/s40001-023-01000-1. PMID: 36642707; PMCID: PMC9841681.
Lin Y, Chen Q, Zhu J, Teng Y, Huang X, Chen X. Progestin-Primed Ovarian Stimulation with Clomiphene Citrate Supplementation May Be More Feasible for Young Women with Diminished Ovarian Reserve Compared with Standard Progestin-Primed Ovarian Stimulation: A Retrospective Study. Drug Des Devel Ther. 2021 Dec 21;15:5087-5097. doi: 10.2147/DDDT.S338748. PMID: 34992345; PMCID: PMC8710074.
Jiang X, Jiang S, Diao H, Deng K, Zhang C. Progestin-primed ovarian stimulation protocol with or without letrozole for patients with normal ovarian reserve: a retrospective cohort study. J Clin Pharm Ther. 2022 Apr;47(4):469-476. doi: 10.1111/jcpt.13567.
Ovarian Stimulation for IVF/ICSI Guideline of the European Society of Human Reproduction and Embryology October 2019
Vaiarelli A, Pittana E, Cimadomo D, Ruffa A, Colamaria S, Argento C, Giuliani M, Petrone P, Fabozzi G, Innocenti F, Taggi M, Ata B, Rienzi L, Ubaldi FM. A multicycle approach through DuoStim with a progestin-primed ovarian stimulation (PPOS) protocol: a valuable option in poor prognosis patients undergoing PGT-A. J Assist Reprod Genet. 2025 Jan;42(1):255-264. doi: 10.1007/s10815-024-03317-0. Epub 2024 Nov 13.
Kalafat E, Turkgeldi E, Yıldız S, Dizdar M, Keles I, Ata B. Outcomes of a GnRH Agonist Trigger Following a GnRH Antagonist or Flexible Progestin-Primed Ovarian Stimulation Cycle. Front Endocrinol (Lausanne). 2022 May 19;13:837880. doi: 10.3389/fendo.2022.837880. PMID: 35663329; PMCID: PMC9161281.
Li Q, Li X, Li T, Xu L, Wang Y, Huang R. Comparison of an HCG-only trigger versus dual trigger for final oocyte maturation in a progestin-primed ovarian stimulation protocol. Reprod Biomed Online. 2022 Dec;45(6):1176-1181. doi: 10.1016/j.rbmo.2022.08.101.
Liang Z, Wang Y, Kuang Y. Live-Birth Outcomes and Congenital Malformations After Progestin-Primed Ovarian Stimulation in Maternal Endometriosis. Drug Des Devel Ther. 2020 Dec 10;14:5459-5467. doi: 10.2147/DDDT.S263138.
Huang J, Xie Q, Lin J, Lu X, Wang N, Gao H, Cai R, Kuang Y. Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019 Jul 26;13:2553-2563. doi: 10.2147/DDDT.S210228.
Zolfaroli I, Ferriol GA, Mora JH, Cano A. Impact of progestin ovarian stimulation on newborn outcomes: a meta-analysis. J Assist Reprod Genet. 2020 May;37(5):1203-1212. doi: 10.1007/s10815-020-01755-0. Epub 2020 Mar 25. PMID: 32215824; PMCID: PMC7244671.
Farquhar C, Rombauts L, Kremer JA, Lethaby A, Ayeleke RO. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. The Cochrane database of systematic reviews 2017;5: Cd006109.
Cédrin-Durnerin I, Carton I, Massin N, Chevalier N, Dubourdieu S, Bstandig B, Michelson X, Goro S, Jung C, Guivarc'h-Lévêque A. Pretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial. Hum Reprod. 2024 Sep 1;39(9):1979-1986. doi: 10.1093/humrep/deae167. PMID: 39008826.
Gleicher N, Mochizuki L, Barad DH. Time associations between U.S. birth rates and add-Ons to IVF practice between 2005-2016. Reprod Biol Endocrinol. 2021 Jul 13;19(1):110. doi: 10.1186/s12958-021-00793-2. PMID: 34256798; PMCID: PMC8278617.
Işıkoğlu M, de Mouzon J. The experience of in vitro fertilization data collection in Turkey. J Turk Ger Gynecol Assoc. 2021 Aug 31;22(3):235-241. doi: 10.4274/jtgga.galenos.2021.2020.0222. Epub 2021 May 3.
European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE); Smeenk J, Wyns C, De Geyter C, Kupka M, Bergh C, Cuevas Saiz I, De Neubourg D, Rezabek K, Tandler-Schneider A, Rugescu I, Goossens V. ART in Europe, 2019: results generated from European registries by ESHRE†. Hum Reprod. 2023 Dec 4;38(12):2321-2338. doi: 10.1093/humrep/dead197.
Glujovsky D, Pesce R, Miguens M, Sueldo C, Ciapponi A. Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle. Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD013827. doi: 10.1002/14651858.CD013827.pub2.
